# An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct06668792/  
OnCo record `nct06668792` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of BCD-248 in multiple myeloma, run by Biocad, now recruiting.

## Summary

An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients With Relapsed/Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT06668792 by Biocad, with 100 participants planned, started 2024-12-26 and due to reach its primary completion in 2026-02. Interventions recorded: BCD-248.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06668792
- Phase: 2
- Setting: An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Subjects With Relapsed/Refractory Multiple Myeloma
- Sponsor: Biocad
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT06668792: https://clinicaltrials.gov/study/NCT06668792

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- companies: [Biocad](https://onco.cc/companies/biocad/)

---
JSON: https://onco.cc/api/v1/entities/nct06668792.json